Información del artículo
Resumen
La artritis reumatoide (AR) es una enfermedad grave que conduce a la destrucción articular, a la pérdida de función y a la muerte prematura. Lograr la inducción de remisión es una meta terapéutica fundamental. El tratamiento con fármacos modificadores de enfermedad (FAME) convencionales en monoterapia raramente permite conseguir y mantener una adecuada respuesta terapéutica a lo largo del curso de la enfermedad. Este artículo revisa el papel de la terapia combinada con FAME convencionales en la AR de reciente comienzo y en la AR evolucionada refractaria. Asimismo, se comenta críticamente el lugar que deberían ocupar estas terapias combinadas en el actual arsenal terapéutico de la AR tras el advenimiento de los nuevos agentes biológicos.
Palabras clave:
Artritis reumatoide
Terapia combinada
Fármacos modificadores de enfermedad
Abstract
Rheumatoid arthritis (RA) is a severe disease that leads to joint destruction, loss of function and premature death. To achieve the induction of remission is a major therapeutic goal. The use of conventional disease-modifying anti-rheumatic drugs (DMARDs) as monotherapy rarely allows to achieve and maintain an adecuate clinical response over the course of the disease. This article reviews the role of the combination therapy with conventional DMARDs in the early-onset and refractory rheumatoid disease. In addition, the role that should play these combination therapies in the current therapeutic armamentarium of RA after the advent of the new biologic agents is critically discussed.
Key words:
Rheumatoid arthritis
Combination therapy
Disease-modifying antirheumatic drugs
El Texto completo está disponible en PDF
Bibliografía
[1.]
Y.S. Sherrer, D.A. Bloch, D.M. Mitchell, D.Y. Young, J.F. Fries.
The development of disability in rheumatoid arthritis.
Arthritis Rheum, 29 (1986), pp. 494-500
[2.]
Y. Matsuda, H. Yamanaka, K. Higami, S. Kashiwazaki.
Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis.
J Rheumatol, 25 (1998), pp. 427-432
[3.]
S.E. Gabriel, C.S. Crowson, W.M. O’Fallon.
Mortality in rheumatoid arthritis: have we made an impact in 4 decades?.
J Rheumatol, 26 (1999), pp. 2529-2533
[4.]
S.E. Gabriel, C.S. Crowson, W.M. O’Fallon.
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.
Arthritis Rheum, 42 (1999), pp. 415-420
[5.]
F. Wolfe, D.J. Hawley.
The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients.
J Rheumatol, 25 (1998), pp. 2108-2117
[6.]
F. Wolfe, D.M. Mitchell, J.T. Sibley, J.F. Fries, D.A. Bloch, C.A. Williams, et al.
The mortality of rheumatoid arthritis.
Arthritis Rheum, 37 (1994), pp. 481-494
[7.]
J. De la Mata, F.J. Blanco, J.J. Gómez-Reino.
Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
Ann Rheum Dis, 54 (1995), pp. 881-885
[8.]
G. Galindo-Rodríguez, J.A. Avina-Zubieta, A.S. Russell, M.E. Suárez-Almazor.
Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
J Rheumatol, 26 (1999), pp. 2337-2343
[9.]
D.T. Felson, J.J. Anderson, R.F. Meenan.
The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis.
Arthritis Rheum, 37 (1994), pp. 1487-1491
[10.]
G. Borg, E. Allander, B. Lund, E. Berg, U. Brodin, H. Pettersson, et al.
Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.
J Rheumatol, 15 (1988), pp. 1747-1754
[11.]
C. Egsmose, B. Lund, G. Borg, H. Pettersson, E. Berg, U. Brodin, et al.
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.
J Rheumatol, 22 (1995), pp. 2208-2213
[12.]
The HERA study group.
A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study.
Am J Med, 98 (1995), pp. 156-168
[13.]
E. Tsakonas, A.A. Fitzgerald, M.A. Fitzcharles, A. Cividino, J.C. Thorne, A. M'Seffar, et al.
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.
J Rheumatol, 27 (2000), pp. 623-629
[14.]
A. Van der Heide, J.W. Jacobs, J.W. Bijlsma, A.H. Heurkens, C. Van Booma-Frankfort, M.J. Van der Veen, et al.
The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial.
Ann Intern Med, 124 (1996), pp. 699-707
[15.]
J.J. Anderson, G. Wells, A.C. Verhoeven, D.T. Felson.
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
Arthritis Rheum, 43 (2000), pp. 22-29
[16.]
C.J. Haagsma, P.L. Van Riel, A.J. De Jong, L.B. Van de Putte.
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.
Br J Rheumatol, 36 (1997), pp. 1082-1088
[17.]
M. Dougados, B. Combe, A. Cantagrel, P. Goupille, P. Olive, M. Chattenkirchner, et al.
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
Ann Rheum Dis, 58 (1999), pp. 220-225
[18.]
M. Boers, A.C. Verhoeven, H.M. Markusse, M.A. Van de Laar, R. Westhovens, J.C. Van Denderen, et al.
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Lancet, 350 (1997), pp. 309-318
[19.]
R.B. Landewe, M. Boers, A.C. Verhoeven, R. Westhovens, M.A. Van de Laar, H.M. Markusse, et al.
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Arthritis Rheum, 46 (2002), pp. 347-356
[20.]
T. Möttönen, P. Hannonen, M. Leirisalo-Repo, M. Nissila, H. Kautiainen, M. Korpela, et al.
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Lancet, 353 (1999), pp. 1568-1573
[21.]
M. Korpela, L. Laasonen, P. Hannonen, H. Kautiainen, M. Leirisalo-Repo, M. Hakala, et al.
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Arthritis Rheum, 50 (2004), pp. 2072-2081
[22.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, H. Julkunen, et al.
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Arthritis Rheum, 50 (2004), pp. 55-62
[23.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, M. Hakala, et al.
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Arthritis Rheum, 52 (2005), pp. 36-41
[24.]
M. Calguneri, S. Pay, Z. Caliskaner, S. Apras, S. Kiraz, I. Ertenli, et al.
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
Clin Exp Rheumatol, 17 (1999), pp. 699-704
[25.]
S.M. Proudman, P.G. Conaghan, C. Richardson, B. Griffiths, M.J. Green, D. McGonagle, et al.
Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
Arthritis Rheum, 43 (2000), pp. 1809-1819
[26.]
A. Marchesoni, N. Battafarano, M. Arreghini, B. Panni, M. Gallazzi, S. Tosi.
Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.
Rheumatology, 42 (2003), pp. 1545-1549
[27.]
A.H. Gerards, R.B. Landewe, A.P. Prins, G.A. Bruyn, H.S. Goei The, R.F. Laan, et al.
Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomized placebo controlled trial.
Ann Rheum Dis, 62 (2003), pp. 291-296
[28.]
P. Sarzi-Puttini, E. D’Ingianna, M. Fumagalli, M. Scarpellini, T. Fiorini, E.L. Cherie-Ligniere, et al.
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.
Rheumatol Int, 25 (2005), pp. 15-22
[29.]
R.F. Willkens, J.T. Sharp, D. Stablein, C. Marks, R. Wortmann.
Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment.
Arthritis Rheum, 38 (1995), pp. 1799-1806
[30.]
M.B. Ferraz, G.R. Pinheiro, M. Helfenstein, E. Albuquerque, C. Rezende, L. Roimicher, et al.
Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.
Scand J Rheumatol, 23 (1994), pp. 231-236
[31.]
C.J. Haagsma, P.L. Van Riel, D.J. De Rooij, T.B. Vree, F.J. Russel, M.A. Van’t Hof, et al.
Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazinetherapy.
Br J Rheumatol, 33 (1994), pp. 1049-1055
[32.]
J.R. O’Dell, C.E. Haire, N. Erikson, W. Drymalski, W. Palmer, P.J. Eckhoff, et al.
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
N Engl J Med, 334 (1996), pp. 1287-1291
[33.]
J.R. O’Dell, R. Leff, G. Paulsen, C. Haire, J. Mallek, P.J. Eckhoff, et al.
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a twoyear, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 1164-1170
[34.]
R. Rau, B. Schleusser, G. Herborn, T. Karger.
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
J Rheumatol, 25 (1998), pp. 1485-1492
[35.]
P. Tugwell, T. Pincus, D. Yocum, M. Stein, O. Gluck, G. Kraag, et al.
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
N Engl J Med, 333 (1995), pp. 137-141
[36.]
M.E. Weinblatt, J.M. Kremer, J.S. Coblyn, A.L. Maier, S.M. Helfgott, M. Morrell, et al.
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Arthritis Rheum, 42 (1999), pp. 1322-1328
[37.]
J.M. Kremmer, M.C. Genovese, G.W. Cannon, R. Caldwell, J.J. Cush, D.E. Furst, et al.
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 137 (2002), pp. 726-733
[38.]
Y.P.M. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, D. Van Zeben, P.J.S.M. Kerstens, J.M.W. Hazes, A.E. Zwinderman, et al.
Clinical and radiological efficacy of different treatment strategies: 2 year follow-up of the BeST study.
Ann Rheum Dis, 64 (2005), pp. 58
[39.]
C. Grigor, H. Capell, A. Stirling, A.D. McMahon, P. Lock, R. Vallance, et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet, 364 (2004), pp. 263-269
Copyright © 2005. Sociedad Española de Reumatología